Stock ETON ETON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Eton Pharmaceuticals, Inc.

Equities

ETON

US29772L1089

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
3.32 USD +0.91% Intraday chart for Eton Pharmaceuticals, Inc. +0.91% -24.20%
May. 09 Transcript : Eton Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09 Eton Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Eton Pharmaceuticals : Letter from KMJ Corbin & Company LLP to Eton Pharmaceuticals, Inc. dated June 21, 2024 Form 8 K
PU
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
GL
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
GL
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
GL
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
AQ
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
GL
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
AQ
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
AQ
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
GL
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
GL
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
GL
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
GL
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
AQ
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
GL
Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
GL
Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
AQ
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
PR
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
GL
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ETON Stock
  4. News Eton Pharmaceuticals, Inc.
  5. Press Releases